Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating the addition of bevacizum...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2022-09, Vol.17 (9), p.1086-1097
Main Authors: Piccirillo, Maria Carmela, Bonanno, Laura, Garassino, Marina Chiara, Esposito, Giovanna, Dazzi, Claudio, Cavanna, Luigi, Burgio, Marco Angelo, Rosetti, Francesco, Rizzato, Simona, Morgillo, Floriana, Cinieri, Saverio, Veccia, Antonello, Papi, Maximilan, Tonini, Giuseppe, Gebbia, Vittorio, Ricciardi, Serena, Pozzessere, Daniele, Ferro, Alessandra, Proto, Claudia, Costanzo, Raffaele, D’Arcangelo, Manolo, Proietto, Manuela, Gargiulo, Piera, Di Liello, Raimondo, Arenare, Laura, De Marinis, Filippo, Crinò, Lucio, Ciardiello, Fortunato, Normanno, Nicola, Gallo, Ciro, Perrone, Francesco, Gridelli, Cesare, Morabito, Alessandro
Format: Article
Language:English
Subjects:
Bevacizumab
EGFR
NSCLC
Randomized clinical trial
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating the addition of bevacizumab to erlotinib as first-line treatment of advanced EGFR-mutated NSCLC. Eligible patients were randomized 1:1 to erlotinib plus bevacizumab or erlotinib alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were coprimary end points. With 80% power in detecting a 0.60 hazard ratio and two-sided α error of 0.05, 126 events of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17. From April 11, 2016, to February 27, 2019, a total of 160 patients were randomized to erlotinib plus bevacizumab (80) or erlotinib alone (80). At a median follow-up of 36.3 months, median investigator-assessed PFS was 15.4 months (95% confidence interval [CI]: 12.2–18.6) with erlotinib plus bevacizumab and 9.6 months (95% CI: 8.2–10.6) with erlotinib alone (hazard ratio = 0.66, 95% CI: 0.47–0.92). Blinded independent centrally reviewed PFS analysis confirmed this result. A statistically significant interaction with treatment effect was found for smoking habit (p = 0.0323), with PFS prolongation being clinically significant only among current or previous smokers. Hypertension (grade ≥3: 24% versus 5%), skin rash (grade ≥ 3: 31% versus 14%), thromboembolic events (any grade: 11% versus 4%), and proteinuria (any grade: 23% versus 6%) were more frequent with the combination. The addition of bevacizumab to first-line erlotinib prolonged PFS in Italian patients with EGFR-mutated NSCLC; toxicity was increased with the combination but without unexpected safety issues.
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2022.05.008